Inhaled allergen challenge is a highly reproducible, integral disease model enabling the investigation of several features of asthma ([@CIT0001]). Allergen challenge can be applied to study the pathophysiology and, if complemented with (non-)invasive airway samplings, the immunobiology to allergic stimuli within the airways. In drug development, allergen challenge is an established tool predicting clinical efficacy of novel anti-allergic and anti-asthma treatments ([@CIT0002]).

Non-invasive airway sampling by hypertonic saline-induced sputum ([@CIT0003]) has been shown to yield reproducible increases in inflammatory cells and biomarkers following allergen-induced late asthmatic response (LAR) ([@CIT0004]) with subsequent response to novel and existing anti-inflammatory therapies ([@CIT0002], [@CIT0004]--[@CIT0006]). Although animal studies have provided evidence of TH2 cytokine response following allergen challenge, supported by some human studies applying bronchoscopy ([@CIT0007], [@CIT0008]), no consistent data exist on reproducible quantification of TH2 cytokines and chemokines in sputum. Accountable factors include degradation by standard sputum processing with dithiothreitol (DTT), which destroys the disulfide bounds of these inflammatory markers ([@CIT0009]), overall low baseline concentrations, and relatively insensitive detection techniques. Some of these hurdles could be overcome by physical homogenization of sputum samples by ultracentrifugation, causing cellular disruption with subsequent release of intracellular products, in combination with sensitive detection techniques ([@CIT0010], [@CIT0011]).

Combining sputum ultracentrifugation with novel, sensitive quantification techniques using Meso Scale multi-array microplates ([@CIT0012]) in the allergen challenge model, we aimed to study the following: 1) the feasibility of the quantification of TH2 cytokines and chemokines in sputum at 7 and 24 h post-challenge, 2) their reproducibility, and 3) their reversibility after a short course of inhaled fluticasone (FP). Furthermore, to allow comparison with other established markers of allergen-induced airway inflammation, we also measured the allergen-induced airway responses (i.e. the early asthmatic response \[EAR\] and LAR), exhaled nitric oxide (eNO), sputum cell differentials, and the provocative concentration of methacholine causing a fall in forced expiratory volume in 1 sec (FEV~1~) of 20% (PC~20~FEV~1~methacholine) at baseline and 24 h post-allergen, during all study periods.

Methods {#S0002}
=======

Study population and design {#S0002-S20001}
---------------------------

Thirteen non-smoking subjects participated in a double-blind, two-way crossover study. Participants had clinically stable, mild to moderate allergic asthma ([@CIT0013]), using *prn* short-acting β-2 agonists only and with dual airway responses to inhaled house dust mite (HDM), documented during the single-blind placebo run-in screening period. Each period consisted of three consecutive days, with a washout period ≥3 weeks between periods ([Fig. 1](#F0001){ref-type="fig"}). The screening, allowing to test the reproducibility of the variables, was identical to the subsequent treatment periods, during which subjects randomly received inhaled FP (metered dose inhaler \[MDI\], 500 µg bid, a total of five doses) or matching placebo. On Day 1, baseline measurements including eNO, spirometry followed by methacholine challenge (PC20FEV~1~methacholine), and subsequent sputum induction (3×5 min NaCl 4.5%) were performed prior to study medication. On Day 2, 1 h post-study medication, subjects underwent a titrated allergen challenge ([@CIT0001]). The subsequent airway response was repeatedly measured by FEV~1~ up to 7 h post-allergen. eNO was measured pre-allergen and at 3 h and 7 h post-allergen, the latter measurement followed by sputum induction. At 24 h post-allergen (Day 3), test procedures were repeated as on Day 1 ([Fig. 2](#F0002){ref-type="fig"}). All test procedures were conducted according to standardized, validated methods and at the same time of the day (within 2 h) ([@CIT0001], [@CIT0014]--[@CIT0016]).

![Overview of the single-blind placebo run-in period and double-blind crossover study periods 1 and 2.](ECRJ-2-28319-g001){#F0001}

![Overview of study assessments. IS, induced sputum; eNO, exhaled nitric oxide. Time zero is time of first study medication dosing. The single-blind placebo run-in screening period and the two subsequent study periods were identical.](ECRJ-2-28319-g002){#F0002}

A dual airway response to inhaled HDM extract consisted of an EAR and a LAR, defined as a fall in FEV~1~≥15% from baseline occurring between 0--3 h and 3--7 h post-allergen, respectively.

The study was approved by the Ethics Committee of Leiden University Medical Center, Leiden, The Netherlands, and all participants provided signed informed consent (EUDRACT number 2007-003671-40). All procedures were performed in accordance with the Helsinki Declaration of 1975, revised in 2008.

Study medication and dosing rationale {#S0002-S20002}
-------------------------------------

FP 250 µg/puff (Allen & Hanburys, Glaxo Wellcome Ltd, Middlesex, UK) and matching placebo (Armstrong Pharmaceuticals, Inc., Canton, MA, USA, packaged at Merck Frosst, Kirkland, Canada) were supplied in identical MDIs and inhaled per single puff through an AeroChamber (Volumatic; GlaxoSmithKline, Zeist, The Netherlands). The rationale for the dose regimen was based on a previous study showing substantial reductions in allergen-induced LAR, non-specific airway hyperresponsiveness (AHR), and sputum eosinophils already following one single dose of inhaled FP 250 µg ([@CIT0006]). Thus, to ensure optimal reversal of the allergen-induced inflammatory markers versus placebo, a total of five FP doses (500 µg per dose) were administered throughout the active treatment period.

Allergen challenge {#S0002-S20003}
------------------

The allergen challenge was performed using the 2 min tidal breathing method that has been previously validated ([@CIT0001]). The run-in period served as a dose (range)-finding procedure, whereas during the first and second study periods each subject inhaled the same two or three cumulative doses of the allergen extract that had caused a fall in FEV~1~ of at least 15% from baseline during the run-in period. Following diluent, incremental doubling concentrations (7.81--2,000 BU/mL) of HDM extract (*Dermatophagoides pteronyssinus*; SQ 503, ALK-BPT, ALK-Abelló, Almere, The Netherlands) in phosphate-buffered saline (PBS) (Invitrogen cat. no. 14040) were aerosolized by a calibrated jet-nebulizer (DeVilbiss 646, output 0.13 mL/min, Somerset, PA, USA) and inhaled at approximately 12 min intervals, until the EAR was reached (defined as a decrease in FEV~1~ of ≥15% from post-diluent baseline within 1 h post-allergen). Airway response to inhaled allergen was measured by FEV~1~ in duplicate on a calibrated spirometer (Vmax Spectra; Sensor Medics, Bilthoven, The Netherlands) according to standard procedures ([@CIT0017]), at 10, 20, 30, 45, 60, 90, and 120 min and then hourly until 7 h after the last allergen inhalation. The highest technically valid measurement was expressed as percentage decrease from the post-diluent baseline FEV~1~ and included in the analysis.

Methacholine challenge {#S0002-S20004}
----------------------

The methacholine challenge was performed using standard methodologies ([@CIT0015]). Serial doubling concentrations of methacholine bromide (MBr; Janssen Pharmaceutical, Beerse, Belgium), diluted in normal saline (NaCl 0.9%) to serial doubling dilutions of 0.15--80 µmol/mL, were aerosolized by a calibrated jet nebulizer (DeVilbiss 646) at 5-min intervals and inhaled by the subjects by tidal breathing for 2 min through the mouthpiece with the nose clipped. Airway response was measured by FEV~1~ at 30 and 90 sec (and potentially at 180 sec as well) following each concentration, and the lowest technically satisfactory FEV~1~ was incorporated into the analysis. Nebulization was continued until a ≥20% fall in FEV~1~ from the post-diluent baseline.

After both bronchoprovocation tests, subjects received salbutamol through an AeroChamber, until the FEV~1~ returned to within 10% of the baseline value.

Exhaled nitric oxide {#S0002-S20005}
--------------------

All eNO measurements were performed according to current guidelines ([@CIT0014]) using a chemiluminescence analyzer (Ecomedics CLD88sp; Ecomedics, Duernten, Switzerland), which had to be replaced by a NIOX MINO^®^ (Aerocrine AB, Solna, Sweden) during the study. The NIOX MINO was used for subjects 8, 9, 10, 11, 12, and 13 during both study periods. In a previous study at our institute, both analyzers yielded similar values ([@CIT0018]).

Sputum induction, processing, and analysis {#S0002-S20006}
------------------------------------------

Sputum induction was performed as previously described ([@CIT0016], [@CIT0019]) using a DeVilbiss Ultraneb 2000 ultrasonic nebulizer (Tefa Portanje, Woerden, The Netherlands) connected to a 100-cm long plastic tube, with an internal diameter of approximately 22 mm, connected to a two-way valve (No. 2700; Hans-Rudolf, Kansas City, MO, USA) with a mouthpiece. Hypertonic saline (NaCl 4.5%) was nebulized and inhaled through the mouth, with the nose clipped, during three periods of 5 min. At approximately 7 min after each induction, spirometry was performed as a safety measure.

Collected sputum samples were divided into two portions of equal weight. The cell pellet of the first portion was processed as a full sample according to guidelines ([@CIT0016], [@CIT0020]), using 0.1% DTT (Sputolysin; Calbiochem, La Jolla, CA, USA). Cell viability and total cell count were assessed using trypan blue; sputum samples containing \>80% squamous cells were excluded from analysis. Differential cell counts were performed by a qualified cytologist on May-Grünwald--Giemsa-stained, coded cytospins and expressed as a percentage of 500 nucleated, non-squamous cells.

The second sputum portion was used to quantify soluble inflammatory markers. At Merck Research Laboratories, defrosted samples were pretreated with a protease-inhibitor cocktail (50 µL per 200 mg sputum), prepared by dissolving one protease cocktail tablet (Complete Protease Inhibitor Cocktail tablets, Roche Applied Science no. 11697498001) into 50 mL of PBS. Prepared sputum samples were subsequently ultracentrifuged in an ultracentrifuge (Optima Max Ultracentrifuge, 130,000 rpm; Beckman Coulter, Inc., Fullerton, CA, USA) at 35,000 rpm (53,500×*g*) for 90 min at 4°C. Subsequently, sputum supernatant was collected and analyzed.

Cytokine and chemokine measurements {#S0002-S20007}
-----------------------------------

Quantification of soluble biomarkers in sputum samples was performed using an MSD (Meso Scale Discovery, Gaithersburg, MD, USA) singleplex kit (IL-13), an MSD duplex kit (eotaxin-3 and TARC), and two MSD multiplex assays (IL-1β, IL-2, IL-4, IL-5, IL-8, IL-10, IL-12p70, IFN-γ, TNF-α, eotaxin, IP-10, MCP-1, MCP-4, and MIP-1β). All concentrations were expressed as pg/mL.

Statistical analysis {#S0002-S20008}
--------------------

Data from all randomized subjects were included in the analysis.

The effect of FP versus placebo on the TH2 cytokines, chemokines, and other inflammatory markers at 7 and 24 h post-allergen was assessed using a mixed-effects analysis of variance (ANOVA) model. The model included fixed factors for sequence, treatment, and period and a random effect for subjects within sequence. Between-treatment differences were estimated by the difference in least-squares means from the model with 90% confidence interval (CI; one-sided alpha=5%). Sputum cell differentials were analyzed using the actual change from baseline, whereas absolute cell counts were analyzed using the change from baseline for the square root transformed values. Geometric mean baseline sputum biomarker concentrations were calculated; half of the lower limit of quantification was used in case of negative outcomes. Changes in sputum biomarker concentrations were analyzed after log transformation and expressed as fold change from baseline.

The airway response to inhaled allergen was expressed as percentage decrease in FEV~1~ from the post-diluent baseline and plotted as time--response curves during all treatment periods. The difference in FEV~1~ during both the EAR and the LAR was analyzed using the time-weighted average of percentage change and the maximum percentage charge from baseline. Subject 1 had an initial FEV~1~ decrease of slightly under 15% at 7 h post-allergen, but met the inclusion criterion at 8 h post-allergen and was included in the study. Therefore, for this subject FEV~1~, cytokines, chemokines, and eNO were consequently measured at 8 h during all periods. FEV~1~ results at 8 h were not included in the analysis.

PC~20~FEV~1~methacholine was calculated by linear interpolation on a plot of log concentrations versus response using methacholine concentrations below and above a 20% fall in FEV~1~. The (allergen-induced and FP-reverted) changes in PC~20~FEV~1~methacholine were expressed in doubling doses. eNO was expressed as a fold change from baseline at 3, 7, and 24 h post-allergen.

Reproducibility of the allergen-induced airway responses and sputum inflammatory markers was assessed using data from the run-in and study placebo periods. The intraclass correlation coefficient (ICC) was calculated, and a two-sided paired *t*-test was performed.

Sample size {#S0002-S20009}
-----------

In the absence of information about variability in TNF-α and IL-13 concentrations in sputum, eosinophil count was used as an approximate variable for sample size estimation ([@CIT0021]). Power calculation showed that the study would have \>90% power (α=0.05, one-tailed) to detect a fivefold increase from baseline at 7 h post-allergen challenge with 12 completing subjects.

Results {#S0003}
=======

Subjects {#S0003-S20001}
--------

After completion of the run-in period, 15 subjects were considered eligible. Before randomization, two subjects were withdrawn: one had a positive cotinine test, whereas the other repeatedly presented with a clinically relevant bronchoconstriction (baseline FEV~1~\<70% predicted). Thus, 13 subjects were randomized and all completed the study ([Table 1](#T0001){ref-type="table"}).

###### 

Baseline characteristics of randomized subjects

  ----------------------------------- --------------------
  Number of subjects                  13
  Age, years                          25.9 (21--43)
  Gender                              4M/9F
  BMI, kg/m^2^                        24.4 (16.6--39.8)
  FEV~1~, L                           3.57 (2.92--4.50)
  FEV~1~, % pred                      94.0 (74.5--112.3)
  PC~20~FEV~1~methacholine, µmol/mL   12.8 (0.8--81.5)
  SPT HDM Wheal, mm                   5.5 (2.5--10.5)
  eNO, ppb                            53.4 (11.2--160.8)
  ----------------------------------- --------------------

Numbers are expressed as mean (range). BMI, body mass index; FEV~1~, forced expiratory volume in 1 sec; SPT HDM, skin prick test for house dust mite; ppb, parts per billion.

Safety {#S0003-S20002}
------

No serious adverse events occurred. Headache and fatigue were the most frequently reported adverse events. All events were mild in intensity and classified as unrelated to the study medication or procedures.

Allergen-induced airway responses {#S0003-S20003}
---------------------------------

Inhaled HDM induced both an EAR and an LAR in all subjects during both placebo periods. Compared to placebo, FP significantly reduced the EAR and completely blunted the LAR ([Fig. 3](#F0003){ref-type="fig"}). The reproducibility of the allergen-induced LAR during both placebo periods was good, both in terms of the maximum percent fall in FEV~1~ from baseline and as time-weighted average (3--7 h post-allergen), with an ICC of 79.7 and 69%, respectively ([Table 2](#T0002){ref-type="table"}).

![Time-response curves (mean±SEM) to inhaled allergen during run-in period, placebo treatment, and fluticasone treatment.](ECRJ-2-28319-g003){#F0003}

###### 

Analysis of the airway response to inhaled allergen

  FEV~1~ endpoint          Treatment                   \% estimate[a](#TF0001){ref-type="table-fn"} (90% CI)   Difference in % change between fluticasone and placebo (90% CI)   One-sided *p*-value[\*](#TF0004){ref-type="table-fn"}   Reproducibility           
  ------------------------ --------------------------- ------------------------------------------------------- ----------------------------------------------------------------- ------------------------------------------------------- ----------------- ------- ------
  EAR time-weighted mean   Placebo                     −7.09 (−8.90, −5.28)                                    5.28 (3.28, 7.28)                                                 \<0.001                                                 4.0 (0.8, 7.3)    0.020   0.0
                           Fluticasone (500 mcg bid)   −1.81 (−3.62, 0.00)                                                                                                                                                                                         
  EAR maximum decrease     Placebo                     −17.7 (−21.3, −14.1)                                    11.12 (8.26, 13.99)                                               \<0.001                                                 6.3 (1.0, 11.7)   0.025   21.3
                           Fluticasone (500 mcg bid)   −6.56 (−10.1, −2.99)                                                                                                                                                                                        
  LAR time-weighted mean   Placebo                     −13.8 (−17.0, −10.6)                                    15.08 (10.97, 19.18)                                              \<0.001                                                 2.6 (−0.8, 6.0)   0.121   69.0
                           Fluticasone (500 mcg bid)   1.28 (−1.89, 4.44)                                                                                                                                                                                          
  LAR maximum decrease     Placebo                     −25.9 (−31.1, −20.7)                                    24.00 (16.70, 31.31)                                              \<0.001                                                 0.0 (−4.7, 4.6)   0.982   79.7
                           Fluticasone (500 mcg bid)   −1.89 (−7.06, 3.28)                                                                                                                                                                                         
  24 h                     Placebo                     −5.30 (−8.16, −2.44)                                    7.05 ( 4.45, 9.64)                                                \<0.001                                                 3.7 ( 0.4, 6.9)   0.030   59.4
                           Fluticasone (500 mcg bid)   1.75 (−1.11, 4.61)                                                                                                                                                                                          

Percentage change from period baseline

placebo period vs. (placebo) run-in period

paired *t*-test

EAR, early asthmatic response; LAR, late asthmatic response; CI, confidence interval; ICC, intraclass correlation coefficient.

value: fluticasone vs. placebo, one-sided alpha=5%.

Allergen-induced non-specific AHR {#S0003-S20004}
---------------------------------

During both placebo periods, allergen challenge increased non-specific AHR, by decreasing PC~20~FEV~1~methacholine at 24 h post-allergen by, on average, 1.18 (90% CI: 1.73, 0.64) doubling doses. In contrast, FP increased 24 h post-allergen PC~20~FEV~1~methacholine by on average 1.60 doubling doses (90% CI: 1.06, 2.15), resulting in a mean difference of 2.79 doubling doses (90% CI: 2.07, 3.51; *p*\<0.001) between placebo and FP ([Fig. 4](#F0004){ref-type="fig"}).

![Changes in airway hyperresponsiveness 24 h pre-allergen versus 24 h post-allergen during run-in period, placebo treatment, and fluticasone treatment.](ECRJ-2-28319-g004){#F0004}

Sputum inflammatory cells {#S0003-S20005}
-------------------------

A sputum sample was obtained from all subjects on all occasions. The average squamous cell contamination was 36% (range 2--71%). Of the 117 samples, 16 were not analyzable. Inhaled allergen significantly increased sputum eosinophils both at 7 and 24 h post-challenge during both placebo periods. This effect was significantly reduced by FP ([Table 3](#T0003){ref-type="table"}). The reproducibility for both sputum eosinophil count (ICC 76%) and percentage (ICC 88%) was high at 7 h post-allergen, but poor (ICC 0%) at 24 h.

###### 

Analysis of the eosinophils and neutrophils to inhaled allergen

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Sputum differential     Time (h)   Treatment     \% estimate (90% CI)[a](#TF0005){ref-type="table-fn"}   \% change from baseline Fluticasone vs. placebo (90% CI)   *p*-value[\*](#TF0008){ref-type="table-fn"}   Reproducibility              
  ----------------------- ---------- ------------- ------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------- -------------------- ------- ------
  Eosinophils (count)     7          Placebo\      250.8 (165.5; 336.1)\                                   −277 (−394; −160)                                          0.002                                         −37.4 (−168, 93.5)   0.528   88.1
                                     Fluticasone   −25.9 (−106; 54.5)                                                                                                                                                                            

                          24         Placebo\      217.9 (142.7; 293.0)\                                   −271 (−377; −165)                                          0.001                                         −118 (−244, 8.17)    0.063   0.0
                                     Fluticasone   −52.9 (−128; 22.3)                                                                                                                                                                            

  Eosinophils (percent)   7          Placebo\      11.5 (5.7; 17.4)\                                       −11.8 (−19.9; −3.8)                                        0.014                                                                      
                                     Fluticasone   −0.3 (−5.8; 5.2)                                                                                                                                                                              

                          24         Placebo\      6.8 (1.7; 11.8)\                                        −7.8 (−12.3, −3.3)                                         0.007                                                                      
                                     Fluticasone   −1.1 (−6.1; 3.9)                                                                                                                                                                              

  Neutrophils (count)     7          Placebo\      173.6 (62.5, 284.6)\                                    −101 (−253, 52.0)                                          0.124                                         58.8 (−206, 324)     0.623   15.1
                                     Fluticasone   73.0 (−31.7, 177.7)                                                                                                                                                                           

                          24         Placebo\      224.6 (33.1, 416.2)\                                    −190 (−450, 70.6)                                          0.103                                         219 (−48.2, 487)     0.095   28.0
                                     Fluticasone   35.0 (−157, 226.5)                                                                                                                                                                            

  Neutrophils (percent)   7          Placebo\      −5.5 (−18.8, 7.9)\                                      6.3 (−9.3, 21.8)                                           0.768                                                                      
                                     Fluticasone   0.8 (−11.9, 13.5)                                                                                                                                                                             

                          24         Placebo\      −5.3 (−20.9, 10.3)\                                     −4.6 (−24.7, 15.5)                                         0.335                                                                      
                                     Fluticasone   −9.9 (−25.5, 5.6)                                                                                                                                                                             
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Sputum eosinophils and neutrophils expressed as % change from baseline at 7 and 24 h post-allergen challenge

placebo period vs. run-in period

paired *t*-test.

*p*-value: fluticasone vs. placebo, one-sided alpha = 5%.

Sputum (TH2) cytokines and chemokines {#S0003-S20006}
-------------------------------------

During placebo treatment, inhaled allergen increased sputum inflammatory cytokines and chemokines both at 7 and 24 h post-allergen, yielding the most robust increase at 7 h ([Table 4](#T0004){ref-type="table"}). FP significantly blunted the allergen-induced increases in sputum concentrations of IL-5, IL-13, TARC, eotaxin-3, MCP-1, eotaxin-1, and IL-4 at 7 h post-allergen challenge and of IL-5, IL-13, eotaxin-3, IL-12p70, and MCP-1 at 24 h post-allergen challenge. None of the other sputum soluble markers were significantly affected by FP compared to placebo treatment. At 24 h post-allergen, there were no differences in any sputum inflammatory markers, with the exception of TARC between both placebo treatments.

###### 

Analysis of sputum cytokines and chemokines to inhaled allergen

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  C           Hours post -allergen challenge   Treatment     Estimate[a](#TF0009){ref-type="table-fn"} (90% CI)   \% change (fluticasone vs. placebo) (90% CI), *p*-value[\*](#TF0012){ref-type="table-fn"}   Reproducibility.            
  ----------- -------------------------------- ------------- ---------------------------------------------------- ------------------------------------------------------------------------------------------- ------------------- ------- ------
  IL-5        7                                Placebo\      5.67 (3.63; 8.86)\                                   82.6 (71.4; 89.4)\                                                                          1.27 (0.53; 3.06)   0.555   48.1
                                               Fluticasone   0.99 (0.63; 1.55)                                    p\<0.001                                                                                                                

              24                               Placebo\      2.57 (1.54; 4.30)\                                   66.1 (29.9; 83.6)\                                                                          0.69 (0.24, 2)      0.465   34.7
                                               Fluticasone   0.87 (0.52; 1.46)                                    *p*=0.011                                                                                                               

  IL-13       7                                Placebo\      9.76 (6.25; 15.25)\                                  88.6 (81.2; 93.1)\                                                                          1.13 (0.63; 2.02)   0.655   73.6
                                               Fluticasone   1.11 (0.71; 1.73)                                    *p*\<0.001                                                                                                              

              24                               Placebo\      2.11 (1.52; 2.94)\                                   59.7 (37.0; 74.2)\                                                                          0.66 (0.36, 1.19)   0.148   41.2
                                               Fluticasone   0.85 (0.61; 1.18)                                    *p*=0.002                                                                                                               

  TARC        7                                Placebo\      2.13 (1.68; 2.72)\                                   41.9 (22.8; 56.3)\                                                                          0.9 (0.49; 1.66)    0.709   43.3
                                               Fluticasone   1.24 (0.97; 1.58)                                    *p*=0.003                                                                                                               

              24                               Placebo\      1.75 (1.32; 2.32)\                                   21.4 (−9.4; 43.6)\                                                                          0.49 (0.29, 0.82)   0.012   17.9
                                               Fluticasone   1.37 (1.04; 1.82)                                    *p*=0.108                                                                                                               

  Eotaxin-3   7                                Placebo\      2.24 (1.71; 2.94)\                                   44.6 (18.4; 62.4)\                                                                          1.25 (0.55; 2.81)   0.556   0.0
                                               Fluticasone   1.24 (0.94; 1.64)                                    *p*=0.010                                                                                                               

              24                               Placebo\      2.56 (1.80; 3.63)\                                   39.2 (12.0; 58.0)\                                                                          0.73 (0.29, 1.81)   0.458   22.2
                                               Fluticasone   1.55 (1.09; 2.21)                                    *p*=0.018                                                                                                               

  MCP-1       7                                Placebo\      1.27 (1.03; 1.56)\                                   28.2 (9.1; 43.3)\                                                                           1.14 (0.91; 1.44)   0.230   32.2
                                               Fluticasone   0.91 (0.74; 1.12)                                    *p*=0.015                                                                                                               

              24                               Placebo\      0.96 (0.81; 1.15)\                                   22.8 (4.1; 37.8)\                                                                           1.07 (0.82, 1.4)    0.571   8.0
                                               Fluticasone   0.74 (0.62; 0.89)                                    *p*=0.028                                                                                                               

  Eotaxin-1   7                                Placebo\      2.01 (1.43; 2.82)\                                   47.5 (15.2; 67.6)\                                                                          0.68 (0.36; 1.3)    0.219   52.0
                                               Fluticasone   1.05 (0.75; 1.48)                                    *p*=0.018                                                                                                               

              24                               Placebo\      1.25 (0.89, 1.75)\                                   −0.7 (−61.9, 37.3)\                                                                         0.65 (0.26, 1.63)   0.329   0.0
                                               Fluticasone   1.26 (0.90, 1.76)                                    *p*=0.511                                                                                                               

  IL-4        7                                Placebo\      1.52 (1.21; 1.92)\                                   34.0 (8.9; 52.2)\                                                                           1.02 (0.74; 1.41)   0.899   72.3
                                               Fluticasone   1.01 (0.80; 1.27)                                    *p*=0.021                                                                                                               

              24                               Placebo\      0.98 (0.92, 1.03)\                                   −4.7 (−13.6, 3.5)\                                                                          0.9 (0.72, 1.12)    0.312   0.0
                                               Fluticasone   1.02 (0.96, 1.08)                                    *p*=0.836                                                                                                               

  MCP-4       7                                Placebo\      1.34 (0.96, 1.87)\                                   32.4 (−3.3, 55.7)\                                                                          1.05 (0.6; 1.85)    0.839   0.0
                                               Fluticasone   0.91 (0.65, 1.27)                                    *p*=0.063                                                                                                               

              24                               Placebo\      1.36 (0.98, 1.89)\                                   14.6 (−36.2, 46.5)\                                                                         0.87 (0.44, 1.7)    0.646   1.6
                                               Fluticasone   1.16 (0.83, 1.61)                                    *p*=0.277                                                                                                               

  IL-12       7                                Placebo\      1.47 (0.97, 2.24)\                                   29.0 (−24.9, 59.6)\                                                                         1.56 (0.91; 2.68)   0.095   38.5
                                               Fluticasone   1.05 (0.69, 1.59)                                    *p*=0.149                                                                                                               

              24                               Placebo\      1.61 (1.07; 2.42)\                                   50.6 (12.2; 72.2)\                                                                          0.85 (0.46, 1.54)   0.555   26.5
                                               Fluticasone   0.79 (0.53; 1.19)                                    *p*=0.025                                                                                                               

  IP-10       7                                Placebo\      1.11 (0.85, 1.46)\                                   19.2 (−16.6, 44.0)\                                                                         1.12 (0.64; 1.95)   0.671   0.0
                                               Fluticasone   0.90 (0.69, 1.18)                                    *p*=0.159                                                                                                               

              24                               Placebo\      1.04 (0.71, 1.53)\                                   15.4 (−42.1, 49.7)\                                                                         0.94 (0.52, 1.69)   0.809   0.0
                                               Fluticasone   0.88 (0.60, 1.30)                                    *p*=0.286                                                                                                               

  MIP-1β      7                                Placebo\      1.70 (1.16, 2.48)\                                   17.8 (−40.5, 51.9)\                                                                         1.52 (0.66; 3.52)   0.296   14.6
                                               Fluticasone   1.40 (0.96, 2.04)                                    *p*=0.261                                                                                                               

              24                               Placebo\      1.70 (1.08, 2.67)\                                   −11.9 (−97.1, 36.5)\                                                                        0.8 (0.25, 2.55)    0.687   2.7
                                               Fluticasone   1.90 (1.21, 2.99)                                    *p*=0.637                                                                                                               

  IL-8        7                                Placebo\      1.01 (0.80, 1.28)\                                   4.0 (−31.6, 30.0)\                                                                          0.93 (0.64; 1.36)   0.697   39.3
                                               Fluticasone   0.97 (0.77, 1.23)                                    *p*=0.409                                                                                                               

              24                               Placebo\      1.26 (0.95, 1.66)\                                   8.4 (−35.4, 38.0)\                                                                          0.88 (0.53, 1.46)   0.583   29.9
                                               Fluticasone   1.15 (0.87, 1.52)                                    *p*=0.347                                                                                                               

  IL-10       7                                Placebo\      1.18 (0.94, 1.48)\                                   −1.8 (−40.0, 26.0)\                                                                         1.17 (0.85; 1.63)   0.300   30.5
                                               Fluticasone   1.20 (0.96, 1.50)                                    *p*=0.539                                                                                                               

              24                               Placebo\      1.24 (0.95, 1.61)\                                   9.7 (−17.2, 30.3)\                                                                          0.97 (0.61, 1.52)   0.867   11.0
                                               Fluticasone   1.12 (0.86, 1.45)                                    *p*=0.247                                                                                                               

  IL-1β       7                                Placebo\      1.02 (0.77, 1.34)\                                   −10.6 (−60.0, 23.6)\                                                                        1.02 (0.64; 1.62)   0.933   42.6
                                               Fluticasone   1.12 (0.85, 1.48)                                    *p*=0.684                                                                                                               

              24                               Placebo\      1.17 (0.80, 1.72)\                                   3.2 (−45.1, 35.5)\                                                                          1.16 (0.6, 2.28)    0.628   8.9
                                               Fluticasone   1.13 (0.77, 1.67)                                    *p*=0.443                                                                                                               

  IL-2        7                                Placebo\      0.90 (0.70, 1.16)\                                   −13.9 (−59.2, 18.5)\                                                                        0.81 (0.64; 1.02)   0.069   72.4
                                               Fluticasone   1.03 (0.80, 1.32)                                    *p*=0.752                                                                                                               

              24                               Placebo\      1.01 (0.72, 1.42)\                                   −19.6 (−79.6, 20.3)\                                                                        0.82 (0.42, 1.6)    0.530   13.4
                                               Fluticasone   1.21 (0.86, 1.70)                                    *p*=0.778                                                                                                               

  IFN-γ       7                                Placebo\      1.05 (0.78, 1.43)\                                   −41.1 (−101, 1.0)\                                                                          1.19 (0.64; 2.23)   0.552   0.0
                                               Fluticasone   1.49 (1.10, 2.02)                                    *p*=0.946                                                                                                               

              24                               Placebo\      1.03 (0.77, 1.38)\                                   −10.8 (−66.7, 26.4)\                                                                        0.84 (0.4, 1.75)    0.611   0.0
                                               Fluticasone   1.14 (0.86, 1.53)                                    *p*=0.670                                                                                                               

  TNF-α       7                                Placebo\      1.14 (0.88, 1.50)\                                   −43.6 (−84.1, −12.0)\                                                                       1.18 (0.73; 1.92)   0.460   0.0
                                               Fluticasone   1.64 (1.26, 2.15)                                    *p*=0.988                                                                                                               

              24                               Placebo\      1.21 (0.93, 1.56)\                                   −4.3 (−43.0, 23.9)\                                                                         0.86 (0.43, 1.71)   0.634   0.0
                                               Fluticasone   1.26 (0.97, 1.63)                                    *p*=0.593                                                                                                               
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Sputum cytokines and chemokines in fold change from baseline at 7 and 24 h post-allergen challenge after placebo and fluticasone treatment

placebo period vs. run-in period

paired *t*-test.

*p*-value: fluticasone vs. placebo, one-sided alpha=5%.

At 7 h post-allergen, many soluble markers were reproducible; in particular, IL-2, IL-4, IL-13, and eotaxin-1 showed ICC values greater than 50%, with more variation between subjects than within subjects. At 24 h, none of the inflammatory markers had ICC values greater than 50%.

Cytokine baseline values on Day 1 for each treatment period are provided in [Table 5](#T0005){ref-type="table"}.

###### 

Mean\* baseline values of cytokines and chemokines during placebo and fluticasone treatment

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Cytokine/chemokine                               IL-5   IL-13   TARC   Eotaxin-3   MCP-1   Eotaxin-1   IL-4   MCP-4   IL-12   IP-10   MIP-1β   IL-8    IL-10   IL-1β   IL-2   IFN-γ   TNF-α
  ------------------------------------------------ ------ ------- ------ ----------- ------- ----------- ------ ------- ------- ------- -------- ------- ------- ------- ------ ------- -------
  Placebo\                                         2.43   1.40    3.69   9.15        21.33   8.55        0.86   4.49    1.99    33.19   9.80     35.17   3.51    10.29   2.98   1.63    3.85
   Day 1 (−3 h)[a](#TF0013){ref-type="table-fn"}                                                                                                                                        

  Fluticasone\                                     2.41   1.41    3.61   8.78        22.85   9.07        0.85   5.50    2.49    39.63   8.91     32.45   3.17    8.73    2.69   1.63    3.48
   Day 1 (−3 h)[b](#TF0014){ref-type="table-fn"}                                                                                                                                        
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Geometric means (pg/mL)

measured −3 h before the start of treatment on study Day 1.

Change in eNO {#S0003-S20007}
-------------

Compared to baseline, eNO levels did not significantly increase at 3 and 7 h post-allergen and did not differ between placebo and FP. At 24 h post-allergen, however, a significant increase in eNO was measured (1.63-fold, 90% CI: 1.2, 2.3), which was blunted by FP (0.83-fold, 90% CI: 0.6, 1.2), resulting in a significant difference between placebo and FP of 49% (*p*=0.012, 90% CI: 19, 68).

Discussion {#S0004}
==========

In this study, we were able to reproducibly quantify several TH2 inflammatory cytokines and chemokines in sputum from allergic asthmatic subjects following inhaled allergen. The increase in these soluble sputum biomarkers was consistent with other established allergen-induced inflammatory responses and was most robust at 7 h post-allergen, coinciding with the maximal fall in FEV~1~ during the LAR. FP significantly blocked both the allergen-induced airway response and the majority of the inflammatory markers in sputum. Although other researchers previously showed a similar inflammatory response in bronchoalveolar lavage ([@CIT0007]) and in sputum ([@CIT0022]--[@CIT0024]), none of them has investigated such wide range of allergen-induced TH2-cytokines and chemokines or their reversibility with corticosteroid treatment.

The use of sulfhydryl-reducing reagents, such as DTT, has complicated the detection of inflammatory cytokines and chemokines, and alternative processing techniques enabling the measurement of eotaxin, for example, have previously been published ([@CIT0009]). In our study, sputum samples were ultracentrifuged ([@CIT0010]), instead of being processed with DTT, to avoid potentially degrading effects on several TH2 cytokines and chemokines ([@CIT0009]). Following this 'boosting' step, substantial allergen-induced increases in several cytokines and chemokines could be reproducibly quantified using sensitive detection techniques (Meso Scale multi-array microplates). However, reproducibility was lost for most soluble markers and sputum eosinophils at 24 h post-allergen.

In parallel with reproducible increases in the TH2-derived inflammatory markers, we were able to demonstrate reproducible changes in the established allergen-induced inflammatory outcome ([@CIT0004], [@CIT0025], [@CIT0026]), including the late asthmatic airway response, non-specific AHR, and sputum eosinophils, underscoring the validity of our data. In agreement with previous evidence, we also found increased eNO levels at 24 h post-allergen ([@CIT0027]), while no significant eNO increases could be observed at our cutoff point during the LAR, specifically, at 7 h post-allergen. Although previous studies showed increased eNO levels at 9 and 10 h post-allergen (([@CIT0027]) and ([@CIT0028]), respectively), the present findings can be explained by the use of two different measuring devices (for logistic reasons) and the time lag required for the synthesis of inducible NO synthase, responsible for the synthesis of NO ([@CIT0029]).

Although no direct comparison was made in the present study with soluble markers from the DTT-processed sputum portion, the current approach yielded reproducible data. In addition, the observation that FP can reverse the allergen-induced increase in these inflammatory markers in parallel with its inhibitory effects on the other inflammatory events, including the airway responses and cellular markers, suggests that this approach is sensitive enough to offer evaluation of therapeutic interventions in asthmatic subjects.

In conclusion, combining novel, sensitive quantification methods with ultracentrifugation allows reproducible quantification of sputum biomarkers following an allergen-induced LAR, which can be reversed by FP. This approach allows non-invasive identification of pharmacodynamic targets for anti-asthma therapies.
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